Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer.

TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July ...

Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy Trodelvy is the ...

Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale. Gilead needs Arcellx more than ever.

Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs. By Matthew Herper Jan. 22, 2024. Reprints. Yichuan Cao/Sipa USA via AP Images.

“Trodelvy has the potential to become a cornerstone treatment in metastatic urothelial cancer, and we are excited about the expected results from the ongoing Phase 3 TROPiCS-04 study that may ...

Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder cancer and only modestly extended the lives of previously treated patients with late-stage lung cancer in a ...

Trodelvy ® Plus Keytruda ® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer – First Pivotal ...

Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months. FOSTER CITY, Calif., May 31, 2025--Gilead Sciences, Inc. ...

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast ...